Data comparing long-term effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplantation are scarce. We compared the effectiveness, pharmacokinetic profile, and safety of LCPT (Envarsus) and PR-Tac (Advagraf) for up to 12 months post-transplant. Adult de novo liver transplant recipients who started IR-Tac (Prograf) and were converted to LCPT or PR-Tac 3-5 days post-transplant were included. Data from 163 patients were analyzed, 87 treated with LCPT and 76 with PR-Tac. The incidence of treatment failure was 30.5% in the LCPT group versus 23.0% in the PR-Tac group (p = .291). Biopsy-proven acute rejection (BPAR) was reported in 26.8% of patients in the LCPT group and 17.6% in the PR-Tac group (p = .166). Graft loss was experienced in one patient (1.2%) in the LCPT group and three patients (4.1%) in the PR-Tac group (p = .346). Death was registered in three patients (3.7%) in the LCPT group and three patients (4.1%) in the PR-Tac group (p > .999). Patients in the LCPT group showed 45.7% higher relative bioavailability (C /total daily dose [TDD]; p < .01) with similar C and 33.3% lower TDD versus PR-Tac (p < .01). The evolution of renal function, safety profile, and the incidence of post-transplant renal failure, dyslipidemia, obesity, hypertension, and diabetes mellitus were similar in patients treated with LCPT and PR-Tac. In de novo liver transplant patients, LCPT and PR-Tac showed comparable effectiveness with higher relative bioavailability, similar C and lower TDD in the LCPT group. Renal function, safety, and post-transplant complications were comparable in LCPT and PR-Tac groups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ctr.15105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of the Once-Daily Tacrolimus Formulation LCPT Compared to the Immediate-Release Formulation in Preventing Early Post-Transplant Diabetes in High-Risk Kidney Transplant Patients: A Randomized, Controlled, Open-Label Pilot Study (EUDRACT: 2017-000718-52).
J Clin Med
December 2024
Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, 38206 La Laguna, Spain.
: Post-transplant diabetes mellitus (PTDM) and prediabetes (PreDM) are common after renal transplantation and increase the risk of cardiovascular events and mortality. Compared to immediate-release tacrolimus (IR-Tac), the LCPT formulation, with delayed absorption, offers higher bioavailability and a smoother time-concentration curve, potentially reducing beta-cell stress. : This randomized pilot trial compared de novo immunosuppression with IR-Tac (twice daily) and LCPT (once daily).
View Article and Find Full Text PDFThe use of once-daily LCP-Tacrolimus with adolescent and young adult solid organ transplant recipients.
Pediatr Transplant
June 2024
Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.
Background: Adolescent and young adult (AYA) solid organ transplant (SOT) recipients experience increased rates of rejection and graft loss surrounding the time of health care transition, in part due to poor medication adherence. This study aims to examine the impact of a once-daily formulation of tacrolimus, LCP-tacrolimus (LCPT), on medication adherence for AYA SOT patients.
Methods: A retrospective descriptive analysis was performed for all patients who underwent SOT and were prescribed LCPT after the age of 12 at our single-center pediatric hospital.
Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study.
Transpl Int
May 2024
CHU Brest, La Cavale Blanche, Brest, France.
Once-daily extended-release tacrolimus (LCPT) exhibits increased bioavailability versus immediate-release (IR-TAC) and prolonged release (PR-TAC) tacrolimus. Improvements in tremor were previously reported in a limited number of kidney transplant patients who switched to LCPT. We conducted a non-interventional, non-randomized, uncontrolled, longitudinal, prospective, multicenter study to assess the impact of switching to LCPT on tremor and quality of life (QoL) in a larger population of stable kidney transplant patients.
View Article and Find Full Text PDFUse of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians.
Ann Transplant
March 2024
Division of Nephrology and Department of Medicine, David Geffen School of Medicine, Los Angeles, CA, USA.
Article Synopsis
- LCPT (Envarsus XR®) is an extended-release tacrolimus used in kidney transplants, but there's a lack of clear guidelines on its dosing and use in new patients or those switching from other forms.
- A group of 12 experts used the Delphi method to create and refine consensus statements on LCPT use, achieving significant agreement on 18 out of 23 generated statements after two rounds of feedback.
- Key findings included that LCPT is recommended as a first-line option for new patients, especially African Americans and rapid metabolizers, and that conversion to LCPT is effective for mitigating neurological side effects from immediate-release tacrolimus.
Early outcomes associated with de novo once-daily extended-release versus twice-daily immediate-release tacrolimus in a predominantly African American kidney transplant population: A single-center observational study.
Clin Transplant
March 2024
Department of Surgery, Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA.
Article Synopsis
- This study examined early outcomes of a new medication, LCPT, compared to the traditional IR TAC in African American kidney transplant patients.
- The study found that while LCPT led to higher tacrolimus levels shortly after transplant, the overall kidney function and key clinical outcomes after one year were similar to those of IR TAC.
- The results suggest that LCPT can be safely used as a first-line treatment post-transplant without increasing complications like delayed graft function.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!